Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, tolerability, and safety of vigabatrin
versus rapamycin as a preventive treatment in infants with Tuberous Sclerosis Complex (TSC).